S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance by Birgitte Grum-Schwensen et al.
Grum-Schwensen et al. BMC Cancer  (2015) 15:44 
DOI 10.1186/s12885-015-1034-2RESEARCH ARTICLE Open AccessS100A4-neutralizing antibody suppresses
spontaneous tumor progression, pre-metastatic
niche formation and alters T-cell polarization
balance
Birgitte Grum-Schwensen2, Jörg Klingelhöfer1, Mette Beck2, Charlotte Menné Bonefeld3, Petra Hamerlik2,
Per Guldberg2, Mariam Grigorian1, Eugene Lukanidin2 and Noona Ambartsumian1*Abstract
Background: The tumor microenvironment plays a determinative role in stimulating tumor progression and
metastasis. Notably, tumor-stroma signals affect the pattern of infiltrated immune cells and the profile of
tumor-released cytokines. Among the known molecules that are engaged in stimulating the metastatic spread of
tumor cells is the S100A4 protein. S100A4 is known as an inducer of inflammatory processes and has been shown
to attract T-cells to the primary tumor and to the pre-metastatic niche. The present study aims to examine the
immunomodulatory role of S100A4 in vivo and in vitro and assess the mode of action of 6B12, a S100A4
neutralizing antibody.
Methods: The therapeutic effect of the 6B12 antibody was evaluated in two different mouse models. First, in a
model of spontaneous breast cancer we assessed the dynamics of tumor growth and metastasis. Second, in a
model of metastatic niche formation we determined the expression of metastatic niche markers. The levels of
cytokine expression were assessed using antibody as well as PCR arrays and the results confirmed by qRT-PCR
and ELISA. T-cell phenotyping and in vitro differentiation analyses were performed by flow cytometry.
Results: We show that the S100A4 protein alters the expression of transcription factor and signal transduction
pathway genes involved in the T-cell lineage differentiation. T-cells challenged with S100A4 demonstrated reduced
proportion of Th1-polarized cells shifting the Th1/Th2 balance towards the Th2 pro-tumorigenic phenotype. The
6B12 antibody restored the Th1/Th2 balance. Furthermore, we provide evidence that the 6B12 antibody deploys its
anti-metastatic effect, by suppressing the attraction of T-cells to the site of primary tumor and pre-metastatic niche.
This was associated with delayed primary tumor growth, decreased vessel density and inhibition of metastases.
Conclusion: The S100A4 blocking antibody (6B12) reduces tumor growth and metastasis in a model of spontaneous
breast cancer. The 6B12 antibody treatment inhibits T cell accumulation at the primary and pre-metastatic tumor sites.
The 6B12 antibody acts as an immunomodulatory agent and thus supports the view that the 6B12 antibody is a
promising therapeutic candidate to fight cancer.* Correspondence: ambartsumian@sund.ku.dk
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In recent years it has become evident that the tumor
microenvironment is deeply engaged in determining the
metastatic fate of the tumor [1]. Many components of
the stroma can influence the metastatic spread of tumor
cells by modulating the molecular network in the tumor
milieu. Similarly, the microenvironment of secondary
organs, where metastases develop, plays a crucial role.
Molecular changes in the microenvironment of second-
ary organs contribute to the formation of pre-metastatic
niches, the future location where cancer cells will reside,
proliferate and develop metastases [2,3].
Therapeutic targeting of cells comprising the tumor
stroma by ablation was suggested as a novel and efficient
way to combat cancer [4]. Immune cells that represent a
substantial component of the stroma in many solid human
tumors exhibit a remarkable dichotomy between tumor-
suppressing and tumor-promoting functions. From a
therapeutic prospective, this plasticity can be used to edu-
cate immune cells to become tumor-suppressing, which is
a more advantageous strategy than simply eradicating
immune stroma cells, as was suggested earlier [5]. For
example, it has been shown that tumor-associated
macrophages, educated to be pro-tumorigenic by T-cell-
produced cytokines, can be re-educated to exhibit tumor
suppressing functions [6].
Similar to macrophages, lymphocytes also play a dual
role in the tumor microenvironment by regulating both
pro- and anti-tumor immunity [7].
Among the numerous molecules of the tumor micro-
environment that play causal roles in metastatic spread
of cancer cells is the S100A4, which belongs to the S100
family of small Ca-binding proteins. This group of pro-
teins is characterized by both intra- and extra-cellular
activity. S100A4 is expressed in many human cancers,
and is correlated with poor prognosis and an elevated
incidence of metastasis [8,9]. By using transgenic and
knockout mouse models stroma-cell derived S100A4 was
shown to have a causal role in tumor progression [10-15].
It has been suggested that it modulates the microenviron-
ment, both at the site of the primary tumor and the pre-
metastatic niche [13,15,16].
Tumor-associated fibroblasts are one of the sources of
extracellular S100A4 in tumors [12,15]. S100A4-positive
fibroblasts produce VEGF-A and tenascin-C, which in
turn contribute to generating a pro-metastatic environ-
ment [15]. Pro-tumorigenic signal transduction pathways
as well as the production of proteases and cytokines from
various cell types are activated by S100A4 [17-20]. Fur-
thermore, it has been shown that S100A4 acts as an angio-
genic factor, as well as attracting T-cells to the site of the
growing tumor and pre-metastatic lungs [11,13,20,21].
Unfortunately, receptors mediating extracellular functions
of S100A4 remain elusive. Several receptors have beensuggested by the research community including RAGE,
TLR-4 and EGFR, pointing to the possibility of multiple-
receptor interaction of S100A4 at the cell surface [22].
Taking into account its pivotal role in metastasis,
S100A4 was suggested as a potential target for a novel
cancer therapy. For examples, the anti-inflammatory drug
sulindac, which inhibits S100A4 transcription, effectively
suppressed colon cancer metastasis [23]. Recently, we have
shown that the S100A4 function-blocking antibody (6B12)
suppressed metastasis formation in mice grafted with
metastatic mammary cancer cells. Furthermore, this study
suggested that, the anti-S100A4 antibody decreased meta-
static burden by blocking the attraction of T-cells [24]. In
vitro, S100A4 was chemo-attractive for T-cells and modi-
fied the pattern of cytokines produced by these cells [13].
Based on the above, we propose that S100A4 might
alter the T-cell balance in the tumor microenvironment
and thereby promote cancer metastasis. We further sug-
gest that blocking S100A4 activity can reinstate the “nor-
mal” T-cell balance and by this suppress the metastasis.
Here we show that S100A4 -challenged T-cells showed
reduced amount of Th1-polarized cells by this altering
the Th1/Th2 polarization balance. The Th1/Th2 bal-
ance is restored by the S100A4 neutralizing antibody.
By implementing two different mouse models we dem-
onstrate that the S100A4 function blocking antibody
suppresses spontaneous tumor progression and pre-
metastatic niche formation which correlates with sup-
pression of T-cell accumulation both at the site of
primary tumor and in pre-metastatic lungs.
Methods
Reagents
RPMI 1640, PBS and FCS were from (Gibco Life Tech-
nologies). Protease inhibitors were from (Roche). Recom-
binant mouse IL2 was from (Miltenyi Biotech). Mouse
IgG and rabbit IgG were from (Sigma-Aldrich, USA). Iso-
lation of the oligomeric form of the S100A4 protein and
the S100A4 mutant (G47W) was described earlier [25,26].
Isolation and characterization of 6B12 anti-S100A4 mouse
monoclonal antibody was described in [24].
Animal experiments
Ethical considerations
All mouse experiments were performed according with
the charter of fundamental animal rights of the European
Union (20007C364/01, Dec 7 2000). Permission to work
with mouse tumor models and breeding of genetically modi-
fied animals has been granted to Noona Ambartsumian by
the Dyreforsøgstilsynet, Fødevarestyrelsen. (Danish Agency
for Animal Experiments, Food Administration) (license
2013-15-2934-00864/ACHOV). All animals were main-
tained according to the FELASA guidelines. All animals
were health checked daily. Tumors were measured at least
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1 cm3 or if they have any clinical signs of illness or distress
due to the tumor burden. Detailed description of experi-
mental procedures was done in accordance with the AR-
RIVE guidelines and could be found in Additional file 1.PyMT mouse model
Virgin female PyMT mice (Polyoma-middle T spontan-
eous metastatic mammary cancer model) of A/Sn genetic
background were used for the experiments. Breeding and
genotyping was performed as described earlier [13]. 6-
week-old PyMT female mice were injected either with a
loading dose (7.5 mg/kg) of 6B12 (n = 20), or IgG control
(n = 20), intra-peritoneal. Injections of antibodies were re-
peated three times a week. 5 animals of each experimental
group were sacrificed at age of 12 weeks. For the rest ani-
mals were sacrificed and processed as described earlier
when the biggest tumor reached 1 cm3 [13].Pre-metastatic assay
CSML100 metastatic mouse mammary carcinoma cells
(1×106) [27] were injected subcutaneously into S100A4
(-/-) mice of A/Sn genetic background [11] followed by
intravenous injection of 2.5×105 S100A4(+/+) or S100A4
(-/-) mouse embryonic fibroblasts (MEFs). Experiment
was repeated twice.
For the analysis of the antibody effect, CSML100 cells
(1×106) were injected subcutaneously followed by intra-
venous injection of 2.5×105 S100A4(+/+) or S100A4(-/-)
mouse embryonic fibroblasts (MEFs) mixed with either
100 μg of 6B12, or IgG control. Then the mice were
injected with a loading dose (7.5 mg/kg) of 6B12, or IgG
control intra-peritoneally three times a week. Injections
of MEFs mixed with antibodies were repeated three
times with a one-week interval. Animals were sacrificed
when the tumor reaches 5-6 mm in diameter (pre-
metastatic phase) [13]. Experiment was repeated twice.Cytokine antibody and PCR array analyses
Pre-metastatic lungs were incubated for 2 hours in PBS
at 37°C. Conditioned media (CM) from five individual
lung cultures were combined in equal ratio and applied to
RayBio Mouse Cytokine Antibody Arrays 3 and 4, allow-
ing simultaneous analysis of 96 cytokines (RayBiotech
Inc.). The assay was performed according to the manufac-
turer’s instructions.
The mouse Th1-Th2-Th3 RT Profiler™ PCR Array
(SABiosciences) was used to determine the relative ex-
pression of 84 genes related to CD4+ T-helper cells, ac-
cording to the manufacturer’s instructions. RayBio Mouse
Cytokine Antibody Array 1 for detecting 22 cytokines was
used to test the cytokine profile in the T-cell CM.Immunohistochemistry
Formalin-fixed paraffin embedded tissue sections were
stained with antibodies against CD3 (rabbit polyclonal,
catalogue #ab5690; Abcam), mouse α-smooth muscle
actin (clone 1A4; Sigma-Aldrich), anti-Fibronectin (FN)
(clone AB-10; Neomarkers), anti-CD31 (clone MEC 13.3)
and anti-CD45 (clone 30 F11), both from BD Biosciences
according to the manufacturer’s protocols.
Corresponding secondary horse-radish peroxidase-
conjugated antibodies (DAKO, Glostrup, Denmark) were
used, followed by incubation with chromogenic substrate
3,3′-diaminobenzidine (DAKO).
For double staining, secondary antibodies coupled to
Alexa Fluor 488 or 568 (1:1500) were purchased from
Molecular Probes. Sections were examined by means of
confocal microscopy on a LSM 510 (Carl Zeiss Inc).
The blood vessel density was determined by quantify-
ing CD31+ capillaries in 3-4 fields from two different
sections of the tumor (magnification, ×200).
Quantification of CD3+ T-cells in tumors from 12-
week-old PyMT mice and in pre-metastatic lungs was
performed as described [13].
Protein expression analysis
Proteins isolated from the pre-metastatic lungs were re-
solved by SDS-PAGE. FN expression was analyzed using
a standard Western-blot procedure with anti-FN (DAKO)
antibodies. Mouse anti-tubulin-α (clone AA13; Sigma-
Aldrich) was used as a loading control. MultiGauge soft-
ware was used for data analysis (Fujifilm).
To test the Jak-Stat signalling pathway activation, puri-
fied T-cells were starved in RPMI 1640 for 3 h and stim-
ulated for 5 and 10 minutes with S100A4 protein (1 μg/
ml), or mixed with 6B12 antibody (6 μg/ml).
Cell lysates were prepared in the presence of protease-
and phosphatase-inhibitors. Activation of the Jak3/Stat3
signalling pathway was analysed using a standard West-
ern blot procedure with phospho-Janus Kinase 3 (Jak3;
Tyr980/Tyr981, clone D44E3), phospho-Signal Transducer
and Activator of Transcription 3 (Stat3; Tyr705, clone
D3A7) and Jak3 (clone D7B12) and Stat3 (clone D3Z2G),
antibodies (Cell Signaling Technology). Each experiment
was reproduced 3 times using independent primary T-cell
isolations.
RNA sample preparation and quantitative real-time
polymerase chain reaction (qRT-PCR)
T-cells purified as described in [13] were stimulated with
S100A4 (1 μg/ml) for 19 h in presence of 10 μg/ml Poly-
myxin B (Invitrogen). Total RNA was isolated using a
NucleoSpin® TriPrep kit (Macherey-Nagel). First-strand
cDNA synthesis was performed using Super-Script III
RT according to the manufacturer instructions. qRT-
PCR was performed using a LightCycler 2.0 instrument
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tive to the housekeeping GAPDH gene, as a control, was
calculated. The PCR analysis was repeated 3 times using
independent primary T-cell isolation. The primers used in
this work are presented in Table 1.T-cell phenotyping
Spleen, thymus and inguinal and brachial lymph nodes
were dissected from 8-week-old A/Sn S100A4(+/+) and
S100A4(-/-) mice [11]. Single-cell suspensions were pre-
pared from the organs. Cells were counted, adjusted to
1 × 107cell/ml and plated in 96-well plates (100 μl/well).
Distribution and activation status of T/B cells was
assessed using a cocktail of primary conjugated antibodies:
anti-CD4 (clone RM4-5), anti-CD8a (clone 53-6.7), anti-
CD19 (clone ID3), anti-TCRαβ (clone H57-597), anti-CD25
(clone PC61), anti-CD44 (clone IM7), or anti-CD62L
(clone MEL-14) (BD Biosciences). Cells were incubated
with the antibodies (1:100) in ice-cold PBS containing 2%
FCS and 0.1% NaN3 for 30 min on ice. Data acquisition
and analysis were performed on aFACSCalibur (BD Bio-
sciences) using FlowJo software (Tree Star).T cell isolation and in vitro differentiation
Primary T-cells were isolated from 3-4 mouse spleens by
negative selection on magnetic bids using the Pan T cell
Isolation Kit II (Miltenyi Biotech), see Grum-Schwensen
et al. for details [13]. Purified T-cells were maintained inTable 1 List of primers used for analysis












































CA-3′RPMI for 3 or 6 days with anti-CD3 or a combination of
anti-CD3 and anti-CD28 antibodies, coupled to MACSi-
beads (Miltenyi Biotec) plus 10 ng/ml recombinant IL2
as described in [28].
Activated T-cells were stimulated with S100A4 pro-
tein (1 μg/ml) or S100A4 protein mixed with 6B12 anti-
body (6 μg/ml). Before fixation, PMA/Ionomycin and
Golgistop™ (BD Biosciences) were added for 5 hours.
Cells were washed with PBS and Fixable Viability Stain
450 (BD Biosciences) was added to discriminate between
viable and dead cells.
Cells were fixed using the Cytofix/Cytoperm™ kit (BD
Biosciences) and stained with the mouse Th1/Th2/Th17
phenotyping kit (BD Biosciences) containing antibodies
against CD4, IL17A, IFNγ and IL4 according to the
manufacturer’s instructions. Data acquisition and ana-
lysis were performed on a FACSVerse (BD Biosciences)
using FlowJo software (Tree Star). All experiments were
repeated 3-5 times.
Viability and proliferation assay
Cell viability and proliferation were measured by the
LDH (Roche) and CyQuant® cell proliferation assay kit
according to the manufacturer’s instructions.
ELISA assay
The concentration of the cytokines IL2, IL4, IFNγ and
IL4 in the CM from the T-cell cultures was measured
using the Mouse Th1/Th2 ELISA assay (eBioscience) ac-
cording to the manufacturer’s instructions. The experi-
ment was performed twice.
Statistical analysis
The confidence level was calculated using paired or un-
paired Student’s t test, depending on the content of the ex-
periment, using GraphPad Prism software. Data is shown
as mean ± SEM.
Results
S100A4 activates T-cell differentiation signalling pathways
As we have shown earlier, the treatment of T-cells
with S100A4 protein in vitro led to the production of
distinct cytokines [13]. This opened up the possibility
that similar changes occurred in the pre-metastatic
lungs in vivo. To test this idea, we implemented the
recently developed mouse model of pre-metastatic
niche formation [13].
Briefly, the metastatic CSML100 mammary carcinoma
cells displayed a suppressed ability to form metastases
when grafted to S100A4(-/-) mice. However, they could
be primed to metastasize by intra-venous administration
of S100A4 expressing fibroblasts (S100A4(+/+)MEFs),
but not by S100A4(-/-) MEFs. In this model we defined
the ‘metastatic stage’ as the point when tumor-bearing
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static stage’ when tumors were small (5-6 mm) and lungs
contained only solitary cancer cells. Notably, S100A4
(+/+), but not S100A4(−/−) MEFs, stimulated the accu-
mulation of T-cells in the lung parenchyma, suggesting
a potential role of T-cells in the formation of a pro-
metastatic milieu [13].
To further characterize the changes that occur in the
pre-metastatic lungs we compared the cytokines released
in pre-metastatic lung organ cultures from S100A4(+/+)
MEF versus S100A4(-/-) MEF boosted tumor-bearing
mice using a cytokine antibody array. This experiment
revealed altered expression of a number of cytokines in-
cluding elevated levels of G-CSF and eotaxin-2 (Table 2).
We also detected an increase in the level of IL4 and IL9
and a decrease in the level of IFNγ and IL1 compared to
control. These might reflect a modulation in the pattern
of T-cells in pre-metastatic lungs. Also noted was the
change in expression of cytokines not involved in T-cell
differentiation, suggesting the complexity of changes that
occur in pre-metastatic lungs.Table 2 Relative expression of cytokines in the
pre-metastatic lung organ cultures isolated from
S100A4(-/-) tumor-bearing mice
Injected cells





eotaxin-2 1 2,21 1,56
G-CSF 1 2,17 1,04
IL6 1 1,99 2,18
fractalkin 1 1,83 1,64
IL9 1 1,79 1,61
Lix 1 0,72 1,58
IL4 1 1,89 1,50
M-CSF 1 1,52 1,25
KC (GRO-alpha) 1 1,44 1,19
MIP-1-gamma 1 1,22 1,42
SDF-1alpha 1 2,11 1,39
IGFBP6 1 1,43 2,03
IL1-alpha 1 0,67 1,31
IL1-beta 1 0,41 1,60
L-selectin 1 0,59 0,95
lymphotactin 1 2,15 1,65
MCP1 1 1,62 1,26
PF4 1 0,77 2,31
IFN-gamma 1 0,77 0,82
ctack 1 0,68 1,42We further performed gene expression profiling of
S100A4-stimulated primary T-cells that revealed changes
in the expression of genes responsible for the differenti-
ation of CD4+ T-cells (Additional file 2: Table S1). The
differential expression of selected genes was validated by
independent experiments using qRT-PCR (Figure 1A).
While S100A4 had little effect on the transcription of
GATA3 and TGF-β, the transcription of IL6, IL10, Jak3,
Tyk2, CD40 and CTLA4 was substantially increased in
S100A4-treated primary T-cells. To further validate the
results of gene expression profiling, we examined the level
of selected cytokines produced by S100A4-stimulated T-
cells. This analysis confirmed the previously observed in-
crease in IL6, IL2 and IL10 levels. We also detected an
increase in the production of IL9, IL17, IL13 and decrease
in IFNγ. The complete list of differentially expressed cyto-
kines is presented in the Additional file 2: Table S2.
The resulting data also demonstrated that S100A4 mod-
ulates the expression of transcription factor and signal
transduction pathway genes involved in determining the
fate of T-helper lineage. Alteration of T-cell polarization
could be predicted based on the up-regulation of Jak3,
Stat1, Socs3, Tyk2 as well as down-regulation of Tbx21
(t-bet), GATA3, Socs1 and Socs5 [29].
We next tested whether S100A4 could activate the
Jak/Stat pathway which is known for its implication in
the lineage differentiation of T-cells [30]. Western blot
analyses of Jak3 and Stat3 phosphorylation of T-cell
protein extracts showed strong activation of Jak3 and
modest activation of Stat3 upon S100A4 treatment,
whereas the S100A4 mutant protein did not activate
the phosphorylation (Figure 1B and C). Moreover, the
S100A4-neutralizing 6B12 antibody efficiently blocked
phosphorylation of both, Jak3 and Stat3 (Figure 1B and C).
These results opened the possibility that S100A4 affects
T-cell differentiation via activation of the Jak/Stat pathway.
Analysis of cytokine antibody and gene expression
arrays directed us to study the effect of S100A4 on the
T-cell differentiation.
S100A4 alters the Th1/Th2 balance of differentiating
T-cells by reducing the amount of Th1-polarized cells
We next assessed the long-term effect of S100A4 on T-
cells. Isolated primary T-cells were primed to proliferate
by CD3 and propagated for 3 and 6 days with or without
S100A4. The percentage of live cells (data not shown) as
well as the percentage of CD4+ in both cultures at 3 and
6 days was similar (Figure 2A), suggesting that S100A4
did not alter the population of CD4+ T-cells. The CD4+
T-cell fraction was further analysed to establish changes
in the T-helper cell populations. The Th1/Th2 ratio at
3 days and Th2/Th17 ratio at 3 and 6 days remained un-
changed by S100A4-treatment (data not shown). In con-
trast, at 6-days the percentage of Th1-polarized cells in
Figure 1 S100A4 activates T-cell differentiation pathways in vitro. (A) Relative expression of IL6, IL10, Jak3, Tyk2, CD40, CTLA4, GATA3 and
TGF-β as determined by qRT-PCR of RNA isolated from T-cells treated with the S100A4 protein. *, P < 0.05; **, P < 0.01. (B) Phosphorylation of Jak3
in T-cells treated either with S100A4 protein, mutant S100A4 protein, S100A4 protein mixed with 6B12, or 6B12 alone. T-cells were stimulated for
5 and 10 min. Western blot analysis with anti-phospho-Jak3 and anti-Jak3. (C) Phosphorylation of Stat3 in T-cells treated with S100A4 protein,
mutant S100A4 protein, S100A4 protein mixed with 6B12, or 6B12 alone. T-cells were stimulated for 5 and 10 min. Western blot analysis with
anti-phospho-Stat3 and anti-Stat3 antibodies.
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the fraction of Th2-polarized cells remained unaffected
(Figure 2B and C). Priming S100A4-treated T-cell with
CD3/CD28/IL2, to stimulate production of Th1-polarized
cells, did not reverse the situation (Additional file 2: Figure
S1). Relative Th1/Th2 ratios showed a significant shift to-
wards prevalence of Th2 polarized cells in the S100A4-
treated cultures (Figure 2D). Treatment of the cultures
with the 6B12, the S100A4-neutralizing antibody, par-
tially restored the Th1/Th2 balance in the S100A4-
treated population indicating that the effect was S100A4
dependent (Figure 2E).
To confirm changes of the Th1/Th2 balance in the
S100A4-treated cultures, we determined the level of IFNγ,IL4 and IL10 signature cytokines in the CM. Sandwich
ELISA analyses showed a reduction of IFNγ and increase
in the IL10 in the CM of S100A4-challenged T-cells
(Figure 2F). The concentration of IL4 in samples was
below limit necessary for detection (data not shown).
Blocking S100A4-induced T-cell accumulation inhibits
spontaneous tumor development and metastasis
The anti-S100A4 monoclonal antibody, 6B12, exhibited
anti-metastatic activity by blocking T-cell infiltration in
a tumor graft mouse model [24]. Injecting fully trans-
formed cancer cells does not allow for studying the early
steps of cancerogenesis. In order to develop the antibody
as a potential therapeutic treatment, the assessment of
Figure 2 S100A4 shifts the Th1/Th2 balance of differentiating T-cells in vitro. (A) The percentage of CD4+ T-cells in S100A4-treated and
control T-cell populations at 3 and 6 days. (B) Representative pictures of the flow cytometry analysis of primary Th1/Th2 polarized CD4+ T-cells.
Primary T-cells were expanded with or without S100A4 protein for 6 days. (C) The percentage of Th1-polarized CD4+ T-cells in the S100A4-treated
and control populations. (D) The relative ratio of Th1/Th2 polarized T-cells after stimulation with S100A4 protein for 3 and 6 days. (E) The relative
ratio of Th1/Th2 cells after stimulation of T-cells for 6 days with the S100A4 protein or with S100A4 protein mixed with 6B12. (F) Determination
of IFNγ and IL10 levels in CM from T-cells expanded with or without S100A4 protein for 6 days by Sandwich ELISA. Data are in triplicate.
*** P < 0.001.
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cer development is especially important. For this purpose
we used a PyMT-spontaneous metastatic mammary can-
cer mouse model [31].
Administration of 6B12 to PyMT tumor-bearing mice
led to a delay in the development of tumors and reduc-
tion in the rate of tumor growth (Figure 3A). This delay
in tumor growth could be caused by the suppression of
the pro-angiogenic function of S100A4 [10,21]. We there-
fore determined tumor vessel density by staining tissuesections with the endothelial-specific anti-CD31 antibody.
Indeed, quantifying capillaries in the tissue sections,
demonstrated a substantial decrease in vessel density in
tumors of 6B12-treated animals compared to the control
(Figure 3B).
We next analysed whether the 6B12 antibody was able
to block T-cell infiltration in pre-malignant tumors. The
resulting data showed that 6B12 significantly reduced
the accumulation of T-cells in primary tumors at the ad-
enoma (MIN)/early carcinoma stage (Figure 3C).
Figure 3 (See legend on next page.)
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Figure 3 6B12 antibody suppresses primary tumor and lung metastasis development and inhibits T-lymphocyte attraction in the PyMT
model. (A) Primary tumor growth of PyMT mice treated with 6B12 (n = 15) or IgG control (n = 21). (B) Upper panel: Representative images of
blood vessel density in the tumor tissue sections from tumor-bearing mice treated with 6B12 and IgG (immunostaining with anti-CD31 antibody.
Bar, 50 μm. Lower panel: Vessel density of primary tumors developed in PyMT mice treated with 6B12 (n = 6) or IgG control (n = 9). (C) Upper
panel: Representative images of tumor tissue sections from 12 week-old PyMT mice treated with 6B12 antibody or with IgG control stained with
anti-CD3 antibody. Bar, 50 μm. Lower panel: Quantification of CD3+ T-lymphocytes in the vicinity of primary tumor lesions from 12-week-old
PyMT mice treated with 6B12 (n = 5) or IgG control (n = 8). (D) Metastatic burden in the lungs of PyMT mice treated with 6B12 (n = 15) or IgG
control (n = 21). (E) Number of metastatic foci per lung per mouse in PyMT mice treated with 6B12 or IgG control.
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well as the overall number of metastases in the lungs of
6B12-treated mice, showed a significant reduction of
both parameters when compared with the control group
(Figure 3D and E). This data indicated that 6B12 was
instrumental in manipulating tumor growth as well as
metastasis formation when applied during early tumor
development.
The pre-metastatic niche is suppressed by the S100A4
neutralizing antibody
The reduced number of metastatic nodules in lungs of
6B12 treated PyMT-mice suggests that it could affect the
formation of the pre-metastatic niche. We therefore ana-
lysed the efficacy of the 6B12 antibody in blocking the
pre-metastatic niche by monitoring hallmarks of pre-
metastatic niche formation, such as the deposition of FN,
the production of G-CSF and the accumulation of T-cells
[13,32,33]. Tumor-bearing mice at the pre-metastatic stage
were treated with the 6B12 antibody or with the IgG con-
trol. The status of the pre-metastatic niche was analysed
by immunohistochemical staining of lung tissue sections,
which showed increased FN deposits as well as accumula-
tion of T-cells around the blood vessels in pre-metastatic
lungs, of mice boosted by S100A4(+/+)MEFs compared to
the control S100A4(-/-)MEFs (Figure 4A). Quantitative
analysis of FN transcripts in the lungs confirmed increased
FN gene expression in tumor-bearing mice compared to
control mice injected only with S100A4(+/+) MEFs. Indu-
cing pre-metastatic niche formation by boosting mice with
S100A4(+/+) MEFs further increased FN transcription,
although the results were not statistically significant
(Figure 4B). The 6B12 antibody showed a tendency to sup-
press FN transcription (P = 0.093) (Figure 4C), whereas
analysis of FN protein expression showed a significant
reduction of FN in the 6B12- treated group (n = 6,
Figure 4D). Similar to FN, the transcription of G-CSF in
pre-metastatic lungs decreased in response to 6B12 treat-
ment (P = 0.033, Figure 4C). Quantifying the amount of
T-cells accumulated in the vicinity of blood vessels within
pre-metastatic lungs showed that the treatment with the
6B12 antibody led to a substantial reduction in T-cell
numbers compared to the non-treated control (Figure 4E).S100A4(-/-) mice display a reduced number of T-cells in
the spleen
The suppression of tumor development and metastasis
in S100A4(-/-) mice was associated with a decrease in T-
cell infiltration [12,13], suggesting that S100A4 could
affect T-cell production in general. To explore this possi-
bility we performed a detailed analysis of the T-cell com-
partment of lymphoid organs of S100A4(-/-) mice.
Analysis of thymus, spleen and lymph nodes of S100A4
(+/+) and S100A4(-/-) mice (n = 12) showed that the over-
all cellularity of organs was similar, with a slight tendency
towards less cellularity in S100A4(-/-) spleens, which was
not statistically significant (Additional file 2: Table S3).
The T-cell population in the thymus of S100A4(-/-)
and S100A4(+/+) mice within the double negative (DN)
compartment, based on the expression of CD44 and
CD25, was not affected by S100A4. Furthermore, the pro-
portion of CD4+ and CD8+ T-cells was similar (data not
shown).
In contrast, the absolute number of CD4+ and CD8+ T-
lymphocytes in S100A4(-/-) spleens was significantly re-
duced compared to the control, whereas the proportion of
CD8+ and CD4+ cells remained unchanged (Figure 5A,B).
We did not observe any differences in the proportion of
naïve (CD62L+CD44-) and memory (CD62L-CD44+)
CD4+ T-cells, as well as naïve (CD62L+CD44-) and mem-
ory (CD62L-CD44+) CD8+ T-cells (data not shown).
The reduction in the absolute number of T-cells in the
spleen of S100A4(-/-) mice could reflect the effect of
S100A4 on the survival of T-cells. This proposition was
of interest since it has been shown earlier that extracel-
lular S100A4 stimulated survival of neurons and the via-
bility of cardiac myocytes [18,34]. We therefore analyzed
growth and survival of T-cell populations in vitro in the
presence of S100A4 for 6 days. As shown in Figure 5C,
S100A4 did not affect the viability of cells as judged by a
LDH cell viability assay. The proliferation rate of T-cells
in culture was also similar.
Discussion
Metastasis is a complex process, which relies on a cross-
talk between emerging cancer cells and the surrounding
stroma, both at the site of the primary tumor and at the
Figure 4 (See legend on next page.)
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Figure 4 6B12 antibody suppresses the formation of the pre-metastatic niche in the lungs. Unless otherwise indicated, the primary tumor
in mice was induced by s.c. injection of CSML100 cells followed by i.v. administration of S100A4(+/+) MEFs. (A) Immunohistochemical staining of
pre-metastatic lung tissue sections from tumor-bearing mice boosted with S100A4(+/+) and S100A4(-/-) MEFs using antibodies against CD3 (red)
and FN (green) (400x magnification). (B) qRT-PCR analysis of FN expression in lungs of tumor-bearing mice non-boosted or boosted with S100A4
(+/+) MEFs. Mice only boosted with S100A4 (+/+) MEFs served as control. (C) qRT-PCR analysis of FN and G-CSF expression in the pre-metastatic
lungs after treatment with the 6B12 antibodies. (D) Quantification of the FN protein expression level in pre-metastatic lungs of mice treated with
the 6B12 antibodies (left panel). Right panel: Western-blot analysis of FN expression in pre-metastatic lungs of mice treated with 6B12 or IgG
control (right panel). (E) Quantification of CD3+ T-cells at the site of blood vessels in pre-metastatic lungs of CSML100 tumor-bearing mice,
co-injected with S100A4(+/+) or S100A4(-/-) MEFs and treated with 6B12 or IgG control (left panel). Representative images of immunofluorescence
staining of pre-metastatic lungs using antibodies against CD3 (green) to visualize T-cells and smooth muscle actin (red) to visualize blood-vessels.
The nucleus is stained by 4′,6-diamidino-2-phenylindole (DAPI, blue). (*, P < 0.05; **, P < 0.01; ***, P < 0.001, 400x magnification, right panel).
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microenvironment could be an efficient route in com-
bating the metastatic disease.
Immune cells, invading the primary tumor site, are im-
portant components of the tumor stroma, indicating that
inflammatory processes substantially influence tumor pro-
gression. Similar to the primary tumor, metastasis forma-
tion is also determined by the presence of a variety of
inflammatory cells in the pre-metastatic organs [35].
It has been shown that, depending on the context,
immune cells in the primary tumor could act as either
anti- or pro-tumorigenic [36,37]. For example, in human
breast cancer a CD68 high/CD4 high/CD8 low T-cell signa-
ture is significantly correlated with reduced patient survival
[38]. Additionally, a high percentage of CD4+ T-cells posi-
tively correlates with tumor stage and metastasis [39].
CD4+ Th2-polarized T-lymphocytes stimulate pulmonary
metastasis by regulating the pro-tumor properties of
tumor-associated macrophages [40]. Finally, blocking
macrophage recruitment in combination with chemo-
therapy substantially improves therapeutic outcomes
in a mouse model system, proving the principle that
targeting immune cells of the tumor microenvironment
could be an efficient way to combat metastasis [38]. Like-
wise, reducing the numbers of Th2-polarized T-cells could
serve as an effective method of anti-metastatic therapy,
since this subpopulation of T-cells has been shown to
regulate macrophage accumulation [40].
The S100A4 protein exhibits, at least in part, its pro-
metastatic function as an extracellular factor produced
by stroma-associated fibroblasts that attracted T-cells to
the tumor site and to the pre-metastatic lungs [12,13].
Moreover, S100A4 is found to be strongly up-regulated in
several different human inflammatory disorders [41-43].
Recently S100A4 has been shown to serve as a link be-
tween metastatic and pro-inflammatory pathways [25].
We therefore suggest that S100A4 in the tumor micro-
environment acts as a pro-inflammatory factor that leads
to modulation of T-cells and propose that neutralizing
S100A4 protein activity might lead to restoration of a“normal” immune microenvironment at the site of the pri-
mary tumor and the pre-metastatic niche.
Pre-metastatic lungs, preconditioned by S100A4(+/+)
MEFs, exhibited an altered cytokine repertoire that sub-
stantially overlapped with the cytokines produced by
S100A4-boosted T-cells [13]. Cytokines, secreted by T-
cells in response to S100A4, showed increased levels of
Th2-characteristic cytokines as well as a decrease in the
level of IFN-γ, suggesting relatively higher representa-
tion of Th2-polarized cells in culture. Recently, we also
reported an S100A4-dependent increase of IL13 pro-
duction in T-cells [41]. This indicates that S100A4 could
induce alterations that lead to a shift in the Th1/Th2
polarization balance.
Moreover, S100A4 activated the Jak/Stat and MAP
kinase pathways in T-cells. In fact, similar to T-cells, the
S100A4 protein activated Jak3/Stat3 and MAP-kinase
pathways in other cell types [17,18]. The Jak3/Stat3 and
MAP-kinase pathways are known to affect T-cell differ-
entiation [30,44-46].
Indeed, this paper has demonstrated an extracellular
S100A4 induced alteration in the Th1/Th2 balance.
S100A4 reduced the percentage of Th1-polarized cells
leading to a shift in the Th1/Th2 ratio. The S100A4-
neutralizing antibody restored it, indicating that the
process was S100A4-dependent. Importantly, the S100A4
protein did not affect proliferation, survival, nor the
proportion of CD4+ T-cells in the population, therefore
suggesting that S100A4’s influence is isolated to T-cell
polarization.
It has been shown that the prevalence of Th2-polarized
cells in the tumor microenvironment is strongly associated
with the metastatic progression of a tumor [7,40,47,48].
Based on this, we propose that S100A4-induced alter-
ations of the Th1/Th2 polarization balance in the tumor
microenvironment can therefore promote tumor pro-
gression. To reach a final conclusion on these proposi-
tions, we will need to obtain in vivo data that directly
links S100A4 with the regulation of T-cell differenti-
ation patterns.
Figure 5 (See legend on next page.)
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Figure 5 S100A4(-/-) mice have smaller CD4+ and CD8+ populations in the spleen. (A) Representative pictures of the flow-cytometry
analysis of CD4+ and CD8+ T-cells from the spleen of S100A4(+/+) and S100A4(-/-) mice. Shown are the average percentages of CD4+ and CD8+
lymphocytes in the spleen (n = 12). (B) The absolute number of CD4+ and CD8+ lymphocytes in the spleen of S100A4(+/+) and S100A4(-/-) mice
(n = 12) determined by flow-cytometry. (C) (i) Cell viability (LDH assay) of primary T-lymphocytes expanded with or without S100A4 protein. The
LDH activity is measured at days 1, 2, 3 and 5. Proliferation rate of primary T-lymphocytes expanded with or without S100A4 protein. (ii) The
number of cells is measured at days 1, 2, 3, 5 and 6.
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tration in pre-malignant tumors and pre-metastatic
lungs, but also suppressed tumor growth and vascu-
lar density, which was not observed earlier in a tumor
graft model [13,24]. We suggest therefore that the pro-
angiogenic activity of S100A4 unfolds at the pre-
malignant stage. Recently, an anti-angiogenic effect of
a different anti-S100A4 antibody was demonstrated in
another model [47].
In addition, S100A4 attracted T-cells to the primary
tumor and pre-metastatic lungs, suggesting that it could
affect the homing of T-cells. Indeed, the number of T-cells
in the spleen of S100A4-deficient mice was reduced,
suggesting that it could distress homing of T-cells to
secondary lymphoid organs. One could speculate that
mechanisms involved S100A4-dependent attraction of
T-cells to the tumor and spleen are similar.
We also suggest here that S100A4-dependent T-cell
activation is essential for its pro-metastatic function.
By utilizing this function S100A4 modifies the tumor
microenvironment and pre-conditions secondary or-
gans to accept tumor cells.
Current cancer treatments, including chemotherapy,
have thus far had a limited effect on metastatic tu-
mors. The data in this paper clearly suggests that
blocking S100A4 activity, using the 6B12 antibody,
should hamper the pro-metastatic activity of the tumor
microenvironment by restoring the T-cell polarization bal-
ance. This, in combination with cytotoxic chemotherapy,
could substantially increase the effectiveness of anti-
cancer treatment in metastatic tumors.Conclusions
Treatment of metastatic disease is one of the biggest
challenges in modern cancer research. Blocking activity
of the pro-metastatic S100A4 protein is suggested as a
promising approach in the fight against metastatic
cancer. Here we show that T-cells, challenged with
S100A4, shift their Th1/Th2 polarization balance to-
wards the Th2 pro-tumorigenic phenotype. The Th1/
Th2 balance is restored by 6B12, a S100A4 neutralizing
antibody. Furthermore, 6B12 suppresses the attraction
of T-cells to the site of the early primary tumor and
pre-metastatic lungs, delays primary tumor growth andinhibits metastases. Overall our data suggests that the
restoration of the T-cell polarization balance at the site
of the primary tumor and the pre-metastatic niche, is a
key mechanism of action of the 6B12 antibody.Additional files
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